Tumor infiltrating lymphocytes (TIL) were cultured from 17 B-cell lymphoma specimens derived from patients with predominantly low-grade malignancies. Specimens included 15 lymph-node biopsies, 1 malignant pleural effusion, and PBL from 1 patient with circulating lymphoma cells. The phenotypic and proliferative characteristics of TIL cultured in interleukin-2 (IL-2) were studied, as well as cytolysis and cytokine secretion in response to autologous tumor. Flow cytometry of fresh tumor suspensions showed that 50% of cells (median) were malignant B cells and 36% were infiltrating T lymphocytes. After culture for approximately 1 month, TIL were 75% f 8% CD3' (mean f SEM), 47% f 8% CD4+ and 35% f 7% CD8'. TIL proliferation was modest in most cases: the median maximum expansion was 32-fold in 25 days. Lysis of autologous tu-
I alone or in combination with lymphokine activated killer (LAK) cells for patients with refractory B-cell nonHodgkin's lymphoma (NHL) has resulted in significant clinical regressions.'s2 The mechanisms of regression are not fully understood but are presumably immune-mediated. Thus, our interest has focused on the T lymphocytes infiltrating these tumors. Previous studies from other laboratories have associated a favorable prognosis for B-cell lymphoma patients with a high content of tumor infiltrating T cells,3 a high percentage of infiltrating CD8+ cytotoxic/sup pressor cells,4 and in vitro proliferation of tumor infiltrating lymphocytes (TIL) in response to autologous tumor stimulation.' Some authors have compared the immune cells infiltrating B-cell lymphoma lymph nodes with those in reactive lymph node hyperplasia. The finding of greater numbers of chronically activated T cells and fewer naive cells in the malignant nodes, suggested an accumulation of memory cells within tumor involved Despite numerous reports characterizing the phenotype of lymphocytes infiltrating B-cell lymphomas and speculating on their possible prognostic significance, limited studies analyzing their in vitro functions are available. In particular, little experience exists with retrieving and culturing CD3+ TIL from patients with lymphoma. In one study, TIL were isolated and cultured under limiting dilution conditions, and their proliferation frequency was noted to be de-0006-4971/93/8204-0009$3.00/0 mor in 4-hour ''Cr release assays was mediated by 2 of 12 TIL studied, but was nonspecific. However, these same two TIL, when cocultured with various tumor stimulators, preferentially secreted tumor necrosis factor-a and granulocyte-macrophage colony-stimulating factor after autologous tumor stimulation; unstimulated TIL secreted undetectable or barely detectable levels of these cytokines. In one TIL culture, cytokines were secreted by purified CD4+ TIL but not by CD8' cells, and secretion was completely abrogated by the anti-major histocompatibility complex (MHC) class II antibody lVAl2. Thus, although specific cytokine secretion by lymphoma TIL in response to autologous tumor was observed, it occurred in fewer than 20% of patients studied. creased when compared with peripheral blood cells from normal donors.' In a separate study, when CD3+ TIL were cocultured with autologous tumor for 6 days, 41% of cultures showed increased proliferation compared with nontumor-stimulated cultures.' The specificity of this response to tumor was not further studied.
The ability of lymphoma TIL to kill autologous tumor has not been well defined, although tumor-specific cytolytic lymphocytes have been identified in the peripheral blood (PB) of one patient with follicular l y m p h~m a .~ TIL may also interact with malignant B cells by suppressing their function. For example, in one study, Ig secretion by malignant B cells was inhibited by T lymphocytes infiltrating these lymphomas." Hence, suggestive evidence exists for host immune reactivity toward lymphoma.
Our group has previously shown that TIL can be expanded under the influence of IL-2 from a variety of solid tumors, including melanomas,"-I3 breast cancers,I4 colon cancers," and renal cell carcinomas.I6 In these studies, the majority of melanoma TIL were cytolytic for autologous tumor, while TIL from other histologies were generally noncytolytic. However, some noncytolytic cultures showed autologous tumor recognition when assayed for secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor-a (TNF-a), and/or interferon-y (IFN-y) in 24-hour cultures. In the current study, using similar culture techniques, we show that CD3+ TIL grown from fewer than 20% of lymphoma patients are capable of autologous tumor recognition, manifested by secretion of GM-CSF and TNF-a. In one instance, cytokine secretion was mediated by CD4+ T cells in an major histocompatibility complex (MHC) class I1 restricted manner.
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script. Cultures were initiated and maintained as previously described.'ls1' Solid lymph-node tissues were minced and enzymatically digested (hyaluronidase type V 0.01%, DNAse type I0.002%, collagenase type IV 0.1%; Sigma, St Louis, MO) for 4 hours at 37°C or up to 24 hours at room temperature. The resultant single-cell suspensions were passed over a Ficoll-Hypaque (Organon Teknika, Durham, NC) density gradient if viability was poor or if there were numerous red blood cells (RBCs). The malignant pleural effusion was obtained by thoracentesis and the cell pellet washed twice in Hanks' balanced salt solution (HBSS). The cell suspensions, containing tumor cells and normal lymphocytes, were cultured in 24-well tissue culture plates (Costar, Cambridge, MA) at a density of 0.5 x lo6 to 1 . O X IO6 cells/mL in media consisting of RPMI 1640 + 10% heat-inactivated human AB serum, 50 IU/mL penicillin, 50 pg/mL streptomycin, 50 pg/mL gentamicin, 250 ng/mL amphotericin, 10 mmol/L HEPES buffer and 2 mmol/L L-glutamine. This media was supplemented with supernatants from 4-day-old allogeneic LAK cell cultures at a concentration of 20% (vol/vol). Recombinant IL-2 (rIL2, specific activity 3.6 X lo6 Cetus U/mg, determined by CTLL assay; 1 Cetus U = 6 IU; kindly provided by the Cetus Corp, Emeryville, CA) was added at a final concentration of 6,000 IU/mL. Cultures were maintained at 37"C, in 5% CO,, and passaged or media replenished every 7 to 10 days. In addition to establishing cultures, samples of the initial tumor-cell suspensions were cryopreserved for later use in various assays.
LAK cell cultures were established from normal donor PBL by methods previously
In brief, lymphocytes were retrieved from the interface of a Ficoll-Hypaque density gradient. They were cultured at 1 X 1 06/mL in RPMI 1640 media containing 2% heat-inactivated human AB serum, antibiotics, HEPES buffer glutamine and 6,000 IU/mL rIL-2. Cultures were maintained in 175 cm2 flasks (Falcon; Becton Dickinson, Oxnard, CA) for 4 to 7 days. The supernatants from 4-day cultures were used, as described above, to supplement TIL cultures. LAK cells were used as effectors in cytolysis assays.
Tumor lines. Daudi, a LAK-sensitive B-cell lymphoma line, was cultured by serial passage in RPMI 1640 + 10% fetal calf serum (FCS). Two Epstein-Barr virus (EBV)-transformed B-cell lines were previously generated from PBL by standard techniques. Cultured melanoma lines were established as describedI7 and serially passaged in the above media. Phenotype analysis. Flow cytometry was performed on fresh tumor suspensions as well as on growing TIL cultures using methods previously described." Antibodies used were anti-Leu-4 (CD3, pan T cell), anti-Leu- Cytotoxicity assays. The cytotoxicity of cultured TIL against fresh cryopreserved and cultured tumor targets was measured in standard 4-hour "Cr release assays, as previously described." Cryopreserved tumors were thawed by rapid rewarming and passed over Ficoll-Hypaque density gradients if viability was less than 50%. The number of tumor cells in each target was estimated by counting all viable cells and multiplying by the percent tumor cells contained in similarly cryopreserved tumor-cell suspensions that had been analyzed by flow cytometry. The ratio of spontaneous/maximum 51Cr release was less than or equal to 30% for all tumor targets except for two (35% for tumor 1103 and 36% for an allogeneic lymphoma in the same experiment).
Measurement of cytokine secretion by TIL. TIL were cocultured with various tumor stimulators, and cytokines were measured in the culture supernatants as previously Briefly, TIL that had received fresh media 5 to 8 days before, were washed twice and plated (1 X 106/well) in 24-well tissue culture plates in 1 mL of media containing 120 IU/mL rIL-2. TIL were either cultured alone or with 5 X lo5 tumor stimulators. In addition, TIL were cultured in the same media containing 120 IU/mL of IL-2 on anti-CD3 monoclonal antibody (MoAb) (OKT3, Ortho Pharmaceuticals, Raritan, NJ) coated tissue-culture plates as a positive control for cytokine production.14 Fresh cryopreserved tumor stimulators were thawed by rapid rewarming and passed over a Ficoll-Hypaque density gradient if viability was less than 50%. A 137Cs source was used to deliver 15,000 rad to fresh tumors and Daudi, and 30,000 rad to a cultured melanoma line. Culture supernatants were collected after 24 hours (or 6 hours for some experiments) and after centrifugation were stored at -70°C. Cytokine measurements were performed on thawed supernatants in duplicate using commercially available enzyme-linked immunosorbent assays (ELISA). Standard curves were generated for each assay and experimental values were computed with the use of regression analysis. If detectable, background cytokine values produced by tumors alone were subtracted from the coculture values when reporting results. Cytokine secretion by TIL was considered relevant when tumor-stimulated values were twofold greater than unstimulated values, and preferential for autologous tumor when twofold greater than allogeneic tumor-stimulated values. GM-CSF was measured with Factor-Test Human GM-CSF ELISA Test Kit (Genzyme, Boston, MA); lowest detectable concentration = 4 pg/mL. TNF-a was measured with Quantikine Human TNF-a Immunoassay (R & D Systems, Minneapolis, MN); lowest detectable concentration = 4.8 pg/mL or with Factor-Test Human TNF-a ELISA Test Kit (Genzyme); lowest detectable concentration = 12.5 pg/mL. IFN--y was measured with Inter Test-y Human IFN-7 ELISA Kit (Genzyme); lowest detectable concentration = 100 pg/mL.
Positive selection of CD4' and CD8+ TIL was performed using tissue culture flasks to which anti-CD4 or CD8 MoAb were covalently bound (Applied Immune Sciences, Menlo Park, CA) as previously des~ribed.",'~ Antibody blocking of TIL cytokine secretion. In an attempt to inhibit TIL cytokine release, tumor stimulators were pretreated with either anti-Thy 1.2, W6/32 (anti-HLA-A, -B, -C, Sera Lab Accurate Chemical and Scientific Corporation, Westbury, NY) or IVA12 (anti-HLA-DR, -DP, -DQ, purified from hybridoma culture supernatants; American Type Culture Collection, Rockville, MD). Tumor cells ( 5 X lo5) in 0.4 mL of media were incubated with 0.1 mL of MoAb for 30 to 45 minutes at room temperature before the addition of TIL (final concentrations of MoAb were 25 to 50 pg/mL). Culture supematants were then collected and cytokines measured as described above.
TIL separation into CD4+ and CD8+ subsets.
RESULTS
Seventeen patients with B-cell lymphomas were studied (Table  1) . Most had stage IV disease and had received multiagent chemotherapy. Their histologic classification according to the Working Form~lation'~ was 12 low, 2 intermediate and 3 high grade. Segments of lymph nodes were obtained from surgical diagnostic biopsies from 15 patients, and a 400-mL thoracentesis specimen was obtained from 1 patient with a malignant pleural effusion. In addition, one patient with circulating malignant cells underwent phlebotomy to obtain PB cells for study ( Table 2 ). All but one of the solid Tumor specimens and TIL culture characteristics.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From lymph node specimens were enzymatically digested as described in the Materials and Methods (tumor 1206 was mechanically disaggregated); the majority of node segments were 1 to 2 cm in greatest dimension. The median number of viable cells retrieved from lymph node specimens was 4.8 X IO8 (range, 1.1 to I7 X 10' ); the median viability was 95% (range, 67% to 100%).
Flow cytometry was performed on fresh cryopreserved tumor cell suspensions and the median percentage of tumor was determined to be 50% from the measurements of various B-cell markers (Table 2) . Infiltrating T cells comprised 36% of cells. A more detailed phenotypic analysis (Table 3) showed that 58% of T cells were CD4' (helper lymphocytes) and 3 I % of T cells were CD8' (cytotoxic/suppressor lymphocytes). In 10 fresh specimens studied, a mean of 67% of CD3+ cells were activated as shown by their coexpression of HLA-DR. Cells expressing the B-cell markers CD 19, CD20 and/or CD22 accounted for 48% to 52% of the total cell number. Monoclonality of these B-cell populations was determined with anti-IgG h or K antibodies and this information was used in differentiating normal from malignant B cells. Normal B cells were rare (4%) or nonexistent except in tumors I 103, I 13 I , and I I57 (containing 6%, 2576, and 6% normal B cells, respectively). As expected, all B cells expressed HLA-DR. Tumor suspensions contained very few NK cells (CD56+, mean 6%) with the exception of specimen 1048 in which these cells were the predominant normal lymphocyte population present.
Seventeen tumor cell suspensions were placed in culture with IL-2 ( Table 2) . Five cultures were established from cryopreserved cells and this did not appear to influence the subsequent lymphocyte proliferation. The median maximum cell proliferation for all cultures was 32-fold (range, 0 Gradet  Theraovt   986  1048  1062  1084  1094  1096  1103  1115  1124  1131  1139  1150  1157  1159  1198  1206  1218   IV  111  111  IV  IV  IV  IV  IV  IV   Ill   IV   Ill  IV  IV  IV  IV cytes/no. of lymphocytes at start of culture.
to 7.4 X lo6). Maximum lymphocyte proliferation occurred on day 25 of culture (range, 14 to 161). One culture was electively terminated when its growth curve had reached a plateau and one culture was terminated because of contamination. The remainder of cultures were maintained beyond the day of their maximum expansion. After a mean of 33 days of incubation, 16 TIL cultures could be phenotyped and were found to contain virtually no tumor cells (CD20-) or monocytes/macrophages (CD 14-) ( Table 4 ). Most cultures were composed predominantly of T cells (mean 75% CD3+). Nine cultures were predominated by CD4+ cells and seven cultures by CD8+ cells. Four cultures (1048, 1084, 1 150, and 1206) contained only 5% to 39% CD3+ cells and greater than 80% CD56+ cells. Interestingly, while tumors 1048 and I 150 contained significant CD56+ cell populations at the outset, tumors 1084 and 1206 contained only 0% and 1 % CD56' cells before culture, respectively.
Cytolysis by 12 B-cell lymphoma TIL after 24 to 76 days in culture was tested in standard 4-hour 51Cr release assays ( Table 5 ). The cytolytic activity of each TIL was tested once and repeated twice for TIL I 13 I . Only 2 of 12 cultures, TIL 1048 and 1 13 1, lysed fresh autologous
Cytolysis by TIL.
For secretion by TIL was measured after cultures were established for 24 to 76 days. TIL (1 X IO6 per/mL) were cultured alone, with irradiated tumor cells (5 X lo5 per/mL) or with immobilized anti-CD3 MoAb for 6 to 24 hours, and GM-CSF, TNF-a, and IFN-7 were measured in the supernatants. GM-CSF secretion is shown in Table 6 . Detectable levels of this cytokine were secreted by unstimulated TIL in 8 of 12 cultures. When TIL were cocultured with autologous tumor, 3 of 12 TIL secreted amounts of GM-CSF more than two-fold greater than unstimulated TIL (TIL 1048, 1084, and 1 13 1). However, when allogeneic tumor targets were cocultured with TIL, preferential cytokine secretion after autologous tumor stimulation was noted in only 2 of 12 cultures, TIL 1048 and 1 131. TIL 1048 secreted 289 pg/mL/24 hours of GM-CSF when stimulated with autologous tumor, but only 8 pg/mL when cultured alone; TIL I131 secreted 243 pg/mL/24 hours when stimulated with autologous tumor, but 13 pg/mL alone. Autologous tumorstimulated cytokine secretion was at least twofold greater than that elicited by any allogeneic tumor stimulator. However, GM-CSF secretion was also observed in response to some allogeneic stimulators (twofold greater than secretion by TIL alone). While it is possible that TIL were reacting to shared tumor antigens presented by common HLA molecules on these allogeneic stimulators, limited amounts of reagents precluded further investigations along these lines.
TIL 1048 and 1131 were simultaneously tested in one criss-cross experiment to further evaluate the specificity of this TIL-tumor interaction. GM-CSF (Table 7) and TNF-a (data not shown) were preferentially secreted by TIL 1048 and 1 13 1 after stimulation by their respective autologous tumors. Little or no secretion was elicited by these tumors when used as allogeneic stimulators, or by tumors from two TIL (1 x 10e/mL) were cultured alone or with irradiated tumor cells (5 X 105/mL) for 24 hours and GM-CSF was measured in the supernatants by ELISA. All tumor alone controls produced t 4 pg/mL of GM-CSF with the exception of tumor 1048 = 61 pg/mL and the allogeneic tumor in exp. 1084 = 41 pg/mL. These values were subtracted from the experimental values.
Abbreviation: ND, not done. other patients. TIL 1048 were tested in two separate experiments (Tables 6 and 7) in which a total of four different allogeneic fresh lymphomas, one allogeneic EBV-B-cell line, and Daudi were used as stimulators. TIL 1 13 1 were tested in three separate experiments (Tables 6, 7 , and 8) in which a total of six different allogeneic lymphomas, one allogeneic EBV-B-cell line, and Daudi were used as stimulators. One experiment with TIL 1131 was performed with purified CD4+ and CD8+ T-cell subsets (Table 8 , discussed below). Of note, all TIL except 1048 secreted large amounts of GM-CSF when cultured on immobilized anti-CD3 MoAb. Table 7 . Specificity of GM-CSF Secretion by Lymphoma TIL 1048 and 113T
GM-CSF Secretion (pg/mL)' For Table 7 .
1131 CD8'TIL TNF-a secretion was measured simultaneously with GM-CSF in all TIL culture supernatants. As for GM-CSF, only TIL 1048 and I 13 1 preferentially secreted TNF-a after autologous tumor stimulation. However, alloreactivity was minimal. These results are depicted in Fig 1. For both TIL 1048 and 1 13 1, autologous tumor-stimulated TIL produced much higher amounts of TNF-a (97 and 87 pg/mL, respectively) than unstimulated TIL (9 and <5 pg/mL respectively) or TIL stimulated by a panel of allogeneic tumors. All 12 TIL cultures secreted high amounts of TNF-a when stimulated with anti-CD3 MoAb ( 12 1 to > 1,000 pg/ mL/24 hours).
In addition to measuring GM-CSF and TNF-a, IFN-7 To investigate the immunologic specificity of the interactions of TIL 1048 and 1131 with autologous tumor, we attempted to inhibit cytokine secretion with anti-MHC MoAb.
Antibody blocking studies with TIL I I3 1 are shown in Table 8 . In the first experiment, unseparated bulk-cultured TIL, containing 76% CD4+ cells and 28% CD8+ cells, secreted GM-CSF and TNF-a in response to autologous tumor stimulation. This secretion was abrogated by the MoAb IVA 12 (anti-MHC class II), indicating a role for CD4+ cells in cytokine secretion. No inhibition was mediated by the irrelevant anti-Thy 1.2 MoAb. While the anti-MHC class I MoAb W6/32 failed to inhibit TNF-a secretion compared with the control without MoAb, it did mediate a 52% reduction in GM-CSF release, suggesting a possible role for CD8+ cells as well. This was further explored with purified CD4+ and CD8+ subsets of TIL 1 13 1. As shown in the second experiment in Table 8 , CD8+ TIL failed to secrete cytokines, while purified CD4+ TIL secreted more cytokine than the unseparated TIL and were markedly inhibited by the IVAl2 MoAb. No cytokine secretion was elicited by four allogeneic lymphomas in these two experiments (data not shown). Thus, these data suggest that CD4+ TIL derived from this lymphoma can recognize autologous tumor in a specific, MHC class 11-restricted manner.
Secretion of GM-CSF and TNF-a by autologous tumorstimulated TIL 1048 could not be blocked by anti-MHC class I or class I1 antibodies (data not shown). This finding is consistent with the surface phenotype of this culture (19% CD3+, 93% CD56') which is characteristic of non-MHC restricted LAK cells. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From breast cancers,l4 and colon cancers.I5 However, little information is available regarding the in vivo function and in vitro properties of B-cell lymphoma TIL. Recent studies showing the clinical responsiveness of some lymphoma patients to IL-2-based immunotherapies's2 suggest that antitumor immune reactivity may be present in such patients. This study of B-cell lymphoma TIL was undertaken to search for in vitro evidence of such immune responsiveness.
We found that fresh tumor-cell suspensions derived from 17 NHL patients were composed of 50% tumor cells, similar to another study.20 Thirty-six percent of cells were T lymphocytes, with CD4' cells predominating over CD8+ cells (mean CD4/CD8 ratio = 2.9). This finding is consistent with other lymphoma studies, in which T lymphocytes accounted for 23% to 4 1% of cells, with CD4/CD8 ratios of 1.4 to 2.4.3,7,20-22 Of note, 67% of T lymphocytes in our study were activated, as shown by their cell-surface expression of HLA-DR. This is slightly higher than the 23% to 48% reported by
Fifteen of 17 TIL specimens proliferated when cultured long-term in the presence of IL-2, resulting in overall maximum expansion of 32-fold on day 25 of culture. This maximum expansion was less and occurred sooner than that reported for TIL from a variety of histologies including melanoma," breast,14 renal cell,I6 and colon ~arcinoma,'~ which had proliferated 2,700-, 6,700-, 68,000-, and 606-fold, respectively, on days 6 1,65, 33, and 49. No such data exist for lymphoma TIL, because this is the first attempt, to our knowledge, to establish long-term lymphoma TIL cultures. Based on their projected expansion, 4 of 17 cultures could have reached the numerical target of 1 X 10" cells that is used in the immunotherapy of melanoma patients.23 Because the majority of specimens obtained were segments of routine lymph-node biopsies, it is likely that greater cell numbers could be generated from larger planned biopsies.
Long-term culture of fresh tumor cell suspensions in IL-2 resulted in the complete disappearance of malignant B cells and the emergence of activated T-cell cultures with a predominance of CD4+ cells. This emergence of CD4+ cells in long-term culture is similar to TIL-derived from renal ce11,I6 breast,I4 and colon1s carcinomas, but contrasts with melanoma TIL cultures that become predominantly CD8+ over time." Interestingly, four lymphoma TIL cultures became predominantly CD56' with low expression of CD3, consistent with a LAK cell phenotype, despite the very small numbers of these cells present in the initial tumor-cell suspensions.
The particular interest of this study was to functionally characterize T lymphocytes grown from lymphoma specimens. The lytic capacity of TIL was tested in 4-hour 51Cr release assays. Significant lysis of autologous tumor was detected in only 2 of 12 cultures tested. One of these, TIL 1048, expressed a LAK cell phenotype and was capable of lysing the MHC class I negative Daudi lymphoma as well as autologous tumor. TIL 1 13 1, which expressed a T-cell phenotype, lysed the autologous tumor at low levels and consequently it was impossible to discern preferential lysis towards the tumor of origin. Even though most fresh lymphoma targets were lysed by allogeneic LAK cells, levels of lysis were generally low and this is comparable with the lysis reported from autologous LAK cells in seven lymphoma patients.24 Hence, the poor cytolytic capacity of Bcell lymphoma TIL, or the intrinsic resistance of tumor targets to lysis, did not allow for the identification of specific MHC-restricted antitumor interactions. This lack of cytolytic activity by TIL is similar to that observed in bread4 and colon cancerT1L.I' In contrast, about one third ofmelanoma TIL cultures exhibit tumor-specific MHC class I-restricted cytolysis of autologous tumor.I2
In searching further for antitumor immune reactivity, cytokine secretion by B-cell lymphoma TIL in response to stimulation with a panel of tumor targets was measured. TIL 1048, which displayed a LAK cell phenotype, preferentially secreted GM-CSF and TNF-a after autologous tumor Stimulation. As expected, this TIL-tumor interaction was not MHC mediated, because cytokine secretion could not be abrogated by anti-MHC class I or class I1 antibodies. It has been reported that LAK cells can secrete TNF and IFNy when stimulated by the erythroleukemia cell line K562.25 In the same study, a panel of leukemia and lymphoma cell lines stimulated LAK cells to secrete cytotoxic factors into the culture supernatants that were capable of killing MCF-7 breast cancer cells. These factors were subsequently found to include TNF and IFN-y, suggesting a direct antitumor role of cytokine secretion by lymphocytes. The specificity of TIL 1048 for autologous tumor in the context ofa LAK cell phenotype also raises the possibility that nonspecific cytokine secretion might be elicited by testing additional stimulators.
TIL 1 13 1 also preferentially secreted GM-CSF and TNFa when stimulated by autologous tumor, which was at least twofold greater than secretion stimulated by a panel of allogeneic tumor stimulators. By isolating subpopulations of T cells, we demonstrated that CD4+ 1 13 1 TIL (and not CD8' TIL) were responsible for this cytokine secretion. These TIL interacted with tumor in a classic MHC-restricted manner, because anti-MHC class I1 MoAb completely abrogated cytokine secretion. The possibility of an autologous mixed lymphocyte reaction could not be completely excluded, because autologous PBL and EBV-transformed B-cell lines were not available for use as stimulators in these cytokine experiments.
Evidence for antitumor immune reactivity by T lymphocytes in B-cell lymphoma, previously unreported for this disease, is not unique to this tumor. Specific cytokine secretion has been described in TIL from melanoma," breast cancer,I4 and colon carcinoma15; experiments with TIL from the first two histologies have included EBV-transformed autologous B cell stimulators as specificity controls. The lower but present reactivity of TIL 1 13 1 with some allogeneic tumors, as evidenced by GM-CSF secretion (but not by TNF-a secretion), raises the possibility of recognition of shared tumor antigens. The phenomenon of specific cytokine release in response to shared tumor antigens on MHC-compatible cells has been shown in TIL from melanoma patients.26 The implications of these findings require -M h e r study.
The in vitro observation of antitumor immune reactivity
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From in B-cell lymphoma TIL suggests a mechanism for the clinical regression of tumor after immunotherapy of select lymphoma patients. Nearly 20% of NHL patients treated with IL-2 (with and without LAK cells) experienced significant tumor regressions. '2' Similar clinical responses have been documented in patients with melan~ma.~' A greater understanding of TIL-tumor interactions will be helpful in developing new immunotherapies for NHL patients.
